CERECOR INC. (NASDAQ:CERC) Files An 8-K Financial Statements and Exhibits

CERECOR INC. (NASDAQ:CERC) Files An 8-K Financial Statements and Exhibits
Item 9.01 of Form 8-K, and this amendment should be read in conjunction with the Original 8-K. Except as set forth herein, no modifications have been made to information contained in the Original 8-K, and the Company has not updated any information contained therein to reflect events that have occurred since the date of the Original 8-K.

Story continues below

Item 9.01. Financial Statements and Exhibits.

(a)Financial Statements of Business Acquired.

The audited financial statements of Ichorion for the period from July 7, 2017 (inception) through December 31, 2017 and the related notes and the unaudited financial statements of Ichorion as of June 30, 2018, and for the six months ended June 30, 2018 and the related notes are attached hereto as Exhibit 99.1 and Exhibit 99.2 and incorporated herein by reference.

(b)Pro-Forma Financial Information.

Unaudited pro forma condensed combined financial information, which includes pro forma condensed combined statements of operation for the year ended December 31, 2017 and the nine months ended September 30, 2018 and the notes related thereto, are filed as Exhibit 99.3 to this report and incorporated herein by reference.

(d)Exhibits.

Exhibit No. Description

23.1

Consent of Independent Auditors.


Cerecor Inc. Exhibit
EX-23.1 2 draftcerecor8-kaconsent.htm EXHIBIT 23.1 Exhibit Exhibit 23.1Consent of Independent AuditorsWe consent to the incorporation by reference in the following Registration Statements (Form S-3 Nos 333-214507,…
To view the full exhibit click here

About CERECOR INC. (NASDAQ:CERC)

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson’s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

An ad to help with our costs